{
  "inputs": {
    "gdsc_path": "data/GDSC2_fitted_dose_response_27Oct23.xlsx",
    "omics_path": "data/OmicsSomaticMutations.csv",
    "model_path": "data/depmap/Model.csv",
    "drug_classes": [
      "ATR",
      "DNA_PK",
      "PARP",
      "WEE1"
    ],
    "z_sensitive_threshold": -0.8,
    "min_margin": 0.25,
    "max_lines": 1000
  },
  "counts": {
    "n_gdsc_rows_after_filter": 9207,
    "n_candidate_model_ids": 945,
    "n_with_omics_mutations": 935,
    "n_missing_omics_mutations": 10
  },
  "label_distribution": {
    "NONE": 694,
    "DNA_PK": 81,
    "ATR": 51,
    "WEE1": 59,
    "PARP": 60
  },
  "top_lineages": {
    "Lung": 162,
    "Lymphoid": 122,
    "Esophagus/Stomach": 62,
    "Skin": 55,
    "CNS/Brain": 55,
    "Breast": 49,
    "Bowel": 48,
    "Myeloid": 42,
    "Ovary/Fallopian Tube": 41,
    "Bone": 40,
    "Head and Neck": 39,
    "Kidney": 36,
    "Pancreas": 31,
    "Peripheral Nervous System": 30,
    "Pleura": 21
  },
  "notes": [
    "This is a preclinical benchmark (cell-line outcomes).",
    "Label is derived from mean GDSC2 Z_SCORE per drug class with ambiguity gating.",
    "Next step: build a balanced evaluation split and run S/P/(DepMap) predictors with Evo2 scoring."
  ]
}